Hořínová Věra, Drábová Klára, Nosková Hana, Bajčiová Viera, Šoukalová Jana, Černá Leona, Hůrková Věra, Slabý Ondřej, Štěrba Jaroslav
Klin Onkol. 2019 Summer;32(Supplementum2):123-127. doi: 10.14735/amko2019S123.
DICER1 syndrome is an inherited disorder that increases the risk of different types of malignant and benign tumors. The syndrome is caused by mutations in the DICER1 gene, which is located on the long arm of chromosome 14, region q32.13. Patients with DICER1 syndrome commonly develop pleuropulmonary blastoma (PPB), multinodular goiter, ovarian Sertoli-Leydig cell tumors, and/or other types of tumors. In approximately 35% of families with children manifesting PPB, further (and rather rare) malignancies may be observed, including cystic nephroma, nodular dysplasia of the thyroid gland, medulloepithelioma of the iris, embryonal rhabdomyosarcoma botryoid type, nasal epithelial hamartoma, pituitary blastoma, and/or pineoblastoma. Large studies report a high variability of tumors associated with DICER1. DICER1 syndrome, which is associated with an inherited predisposition to tumors, is inherited in an autosomal dominant pattern. Symptoms of DICER1 syndrome may vary, even within families. Preventive screening of carriers with causative mutations is complicated. Follow-up is undertaken as recommended by the 2016 International PPB Register. This work was supported by grant of Ministry of Health of the Czech Republic AZV 16-3329A. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 4. 6. 2019 Accepted: 6. 6. 2019.
DICER1综合征是一种遗传性疾病,会增加患不同类型恶性和良性肿瘤的风险。该综合征由位于14号染色体长臂q32.13区域的DICER1基因突变引起。DICER1综合征患者通常会患上胸膜肺母细胞瘤(PPB)、多结节性甲状腺肿、卵巢支持-间质细胞瘤和/或其他类型的肿瘤。在大约35%有儿童表现出PPB的家庭中,可能会观察到进一步的(且相当罕见的)恶性肿瘤,包括囊性肾瘤、甲状腺结节发育异常、虹膜髓上皮瘤、葡萄状胚胎性横纹肌肉瘤、鼻上皮错构瘤、垂体母细胞瘤和/或松果体母细胞瘤。大型研究报告称,与DICER1相关的肿瘤具有高度变异性。与遗传性肿瘤易感性相关的DICER1综合征以常染色体显性模式遗传。DICER1综合征的症状可能各不相同,即使在家族内部也是如此。对有致病突变的携带者进行预防性筛查很复杂。按照2016年国际PPB登记处的建议进行随访。本研究得到了捷克共和国卫生部AZV 16 - 3329A号拨款的支持。作者声明他们在研究中使用的药物、产品或服务方面不存在潜在利益冲突。编辑委员会声明该手稿符合ICMJE对生物医学论文的建议。提交日期:2019年6月4日;接受日期:2019年6月6日。